BioCentury
ARTICLE | Company News

Ipsen doubles down on rare musculoskeletal disease via Blueprint deal

October 16, 2019 9:48 PM UTC
Updated on Oct 16, 2019 at 11:11 PM UTC

Ipsen redoubled its commitment to developing treatments for fibrodysplasia ossificans progressiva by obtaining rights to an ALK2 inhibitor from Blueprint.

The deal gives Ipsen Group (Euronext:IPN; Pink:IPSEY) exclusive, worldwide rights to BLU-782 from Blueprint Medicines Corp. (NASDAQ:BPMC) for $25 million up front. Blueprint is eligible for $510 million in milestones, plus royalties...